Ultragenyx Pharmaceutical Inc. RARE

Rank #2430 · Nasdaq · $1.6B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

19.2

P/E

-2.6

P/B

4.50

ROE

-172.4%

Op. Margin

-131.1%

Debt Ratio

353%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -2.6x, P/B 4.50x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -172.4%. Ranks in the top 94% of the universe.

Safety ★☆☆☆☆

Weak

Debt ratio 353%. Ranks in the top 75% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆

Excellent

Revenue growth of 19.5% year over year. Ranks in the top 20% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	–	$-0.0B	$-0.0B	$-0.0B	–	-120
2015	–	$-0.0B	$-0.0B	$-0.0B	–	-48
2016	–	$-0.1B	$-0.1B	$-0.1B	–	-38
2017	–	$-0.1B	$-0.1B	$0.2B	–	36
2018	$0.0B	$-0.2B	$-0.2B	$0.5B	-186471.4	20
2019	$0.0B	$-0.3B	$-0.3B	$0.5B	-12593.5	23
2020	$0.1B	$-0.4B	$-0.2B	$0.4B	-721.2	126
2021	$0.1B	$-0.4B	$-0.4B	$0.6B	-409.0	99
2022	$0.3B	$-0.3B	$-0.2B	$0.7B	-121.8	92
2023	$0.4B	$-0.4B	$-0.5B	$1.2B	-108.6	103
2024	$0.4B	$-0.6B	$-0.7B	$0.9B	-178.6	132
2025	$0.4B	$-0.6B	$-0.6B	$0.4B	-131.1	353